Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs.
Opinion

When AI Builds Itself: Why Recursive Self-Learning Is the Most Important Concept in Financial Servic

Most financial services executives still encounter AI as a product feature: a better chatbot, a faster credit model, a smarter fraud flag. These are valuable, but they are fundamentally static. Humans ...
Forbes

What's Happening With RXRX Stock?

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
NJBIZ

Bayer, Recursion collaborate on digital drug discovery for fibrotic diseases

Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...
Business Wire

Dr. Imran S. Haque, Biology Machine Learning Expert, Joins Recursion as VP of Data Science

SALT LAKE CITY--(BUSINESS WIRE)--Imran S. Haque, Ph.D., a computer scientist by training, has made a name for himself at the intersection of machine learning and biology by maintaining a high standard ...